Research guide · Cellular Energy
NAD+ — research protocol
Nicotinamide adenine dinucleotide studied for cellular energy and mitochondrial studies.
This guide summarizes study areas and sources associated with the compound. BioPeptideX does not convert experimental information into a clinical regimen or recommend an individual dose, frequency, route or duration.
Catalog presentations
Concentration table
Mathematical reference only; this is not a dosing recommendation.
Research areas
- Cellular energy cofactor
- Longevity
- Lyophilized form
Most-cited research protocols
Educational information based on research protocols and literature; it does not replace guidance from a healthcare professional.
NAD+ is a coenzyme found in every living cell, used to turn food into cellular energy (ATP), fuel DNA repair, and power longevity-related enzymes called sirtuins. This page provides a route-by-route research-context protocol covering various administration formats for NAD+ research.
| Dose | Frequency | Duration | Route | |
|---|---|---|---|---|
| Subcutaneous (SubQ) | N/A | 2-3x weekly | N/A | Subcutaneous injection |
| Intravenous (IV) | N/A | Weekly to monthly | N/A | Intravenous infusion |
| Oral NMN/NR | N/A | Daily | N/A | Oral |
Cycle: Sustained planning typically rotates between SubQ phases and oral precursor bridges beyond 12 weeks.
Benefits and research observations: Immediate (24-48 hours) effects include energy and mental clarity, with SubQ effects potentially taking longer. Weeks 1-4 often show energy and sleep changes, while weeks 4-12 may reveal anecdotal improvements in recovery, exercise capacity, and skin quality.
Handling and storage
Store unreconstituted product according to its label and maintain the cold chain where applicable. After any preparation, follow only validated instructions for the specific product and diluent. Do not use if packaging is damaged or the solution shows particles or unexpected changes.
Warnings
Do not use this page for self-diagnosis or self-medication. Pregnancy, breastfeeding, minors, cancer history, allergies, active disease and concurrent treatments require individual professional evaluation.
Published sources
- 1.Rajman L, et al. Cell Metab, 2018.
- 2.Yoshino J, et al. Cell Metab, 2018.